BioNTech SE (BNTX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
BioNTech SE stock (BNTX) is currently trading at $88.77. BioNTech SE PS ratio (Price-to-Sales) is 7.60. Analyst consensus price target for BNTX is $132.11. WallStSmart rates BNTX as Sell.
- BNTX PE ratio analysis and historical PE chart
- BNTX PS ratio (Price-to-Sales) history and trend
- BNTX intrinsic value — DCF, Graham Number, EPV models
- BNTX stock price prediction 2025 2026 2027 2028 2029 2030
- BNTX fair value vs current price
- BNTX insider transactions and insider buying
- Is BNTX undervalued or overvalued?
- BioNTech SE financial analysis — revenue, earnings, cash flow
- BNTX Piotroski F-Score and Altman Z-Score
- BNTX analyst price target and Smart Rating
BioNTech SE
📊 No data available
Try selecting a different time range
Smart Analysis
BioNTech SE (BNTX) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, price/book. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
BioNTech SE (BNTX) Key Strengths (3)
Growing significantly faster than its price suggests
Large-cap company with substantial market presence
Trading at 1.02x book value, attractively priced
Supporting Valuation Data
BioNTech SE (BNTX) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Revenue declining -23.70%, a shrinking business
Earnings declining -43.20%, profits shrinking
Company is losing money with a negative profit margin
Premium valuation at 7.6x annual revenue
Low institutional interest, mostly retail-driven
Supporting Valuation Data
BioNTech SE (BNTX) Detailed Analysis Report
Overall Assessment
This company scores 35/100 in our Smart Analysis, earning a F grade. Out of 10 metrics analyzed, 3 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 1.1/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Market Cap, Price/Book. Valuation metrics including PEG Ratio (0.04), Price/Book (1.02) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (7.60) suggest expensive pricing. Growth concerns include Revenue Growth at -23.70%, EPS Growth at -43.20%, which may limit upside. Profitability pressure is visible in Return on Equity at -5.88%, Operating Margin at -33.40%, Profit Margin at -39.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -5.88% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -23.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BNTX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BNTX's Price-to-Sales ratio of 7.60x trades at a deep discount to its historical average of 23.97x (39th percentile). The current valuation is 95% below its historical high of 160.62x set in Nov 2020, and 410% above its historical low of 1.49x in Jun 2022.
WallStSmart Analysis Synopsis
Data-driven financial summary for BioNTech SE (BNTX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
BioNTech SE is in a turnaround phase, with management focused on restoring profitability. Revenue reached 2.9B with 24% decline year-over-year. The company is currently unprofitable, posting a -39.6% profit margin.
Key Findings
Generating 238M in free cash flow and 299M in operating cash flow. Earnings are translating into actual cash generation.
Spending 17% of revenue (501M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 24% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -39.6% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Volatility is elevated with a beta of 1.53, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact BioNTech SE.
Bottom Line
BioNTech SE is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About BioNTech SE(BNTX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
BioNTech SE, a biotechnology company, develops and markets immunotherapies for cancer and other infectious diseases. The company is headquartered in Mainz, Germany.